Articles tagged "Immunosuppression"

2022 American Transplant Congress
Defining the Longitudinal Dynamics of Immune Cells in Blood in the First Year After Pediatric Liver Transplantation (pLTx)
E. Chichelnitskiy¹, L. Ruhl², I. Goldschmidt³, A. Karch⁴, L. Antiga⁵, D. Debray⁶, L. Hierro⁷, D. Kelly⁸, V. McLin⁹, E. Nicastro¹⁰, J. Pawlowska¹¹, P. Czubkowski¹¹, R. Mikolajczyk¹², U. Baumann¹³, C. Falk¹⁴
¹Institute of Transplant Immunology, Hannover Medical School (MHH), Hannover, Germany, ²Institute of Transplant Immunology, MHH, Hannover, Germany, ³Division of Pediatric Gastroenterology and Hepatology, MHH; European Paediatric Liver Transplantation Network, Hannover, Germany, ⁴Research Group Epidemiological and Statistical Methods, Helmholtz Centre for Infection Research; German Center for Infection Research, TTU-IICH Hannover; Institute for Epidemiology and Social Medicine, University of Münster, Münster, Germany, ⁵Hannover; Ospedali Riuniti di Bergamo, Bergamo, Italy, ⁶Hannover; Hôpital Necker-Enfants Malades, Paris, France, ⁷Hannover; Hospital Infantil Universitario La Paz, Madrid, Spain, ⁸Birmingham Children's Hospital, Birmingham, United Kingdom, ⁹Service Spécialités Pédiatriques, Genève, Switzerland, ¹⁰Ospedali Riuniti di Bergamo, Bergamo, Italy, ¹¹Gastroenterology, Hepatology, Nutritional Disorders and Pediatrics, The Children’s Memorial Health Institute, Warsaw, Poland, ¹²German Center for Infection Research, TTU-IICH Hannover; MHH; Institute of Medical Epidemiology, Biostatistics and Medical Informatics, University of Halle, Halle, Germany, ¹³Birmingham Children’s Hospital, UK; Division of Pediatric Gastroenterology and Hepatology, MHH, Hannover, Germany, ¹⁴Institute of Transplant Immunology, MHH; German Center for Infection Research, TTU-IICH, Hannover, Germany
*Purpose: In the European multicentre “ChilSFree” study we aimed for a deep characterisation of the longitudinal immune dynamics during the first year after pLTx.*Methods: Absolute…
2022 American Transplant Congress
Ixazomib for Desensitization (IXADES): Results of a Phase II Clinical Trial
N. Wilson¹, S. R. Reese², L. Ptak³, F. Aziz², S. Parajuli², V. Jucaud⁴, S. Denham⁴, A. Mishra⁵, P. Hematti⁵, A. Djamali²
¹University of Wisconsin, Madison, WI, ²Medicine, University of Wisconsin, Madison, WI, ³Administration, University of Wisconsin, Madison, WI, ⁴Terasaki Institute, Los Angeles, CA, ⁵UW Comprehensive Cancer Center, University of Wisconsin, Madison, WI
*Purpose: Ixazomib is a second-generation oral proteasome inhibitor, FDA approved for the treatment of refractory multiple myeloma. The purpose of the study was (1) to…
2022 American Transplant Congress
Variable Course of Hepatitis A Virus Infection in Solid Organ Transplant Recipients
A. Vostal¹, J. Husson², A. Shishido¹, N. Jakhete³, E. Moore⁴, X. Wen⁵, A. Amoroso², R. Meier⁶, E. Wilson², K. K. Saharia²
¹Div. of Infectious Diseases, Univ. of Maryland Medical Center, Baltimore, MD, ²Div. of Infectious Diseases, Univ. of Maryland School of Medicine and Institute of Human Virology, Baltimore, MD, ³Div. of Hepatology, Univ. of Maryland School of Medicine, Baltimore, MD, ⁴Dept of Surgery, Brooklyn Hospital Center, Brooklyn, NY, ⁵Dept. of Surgery, Univ. of Florida, Gainesville, FL, ⁶Dept. of Surgery, Univ. of Maryland School of Medicine, Baltimore, MD
*Purpose: Although Hepatitis A virus (HAV) infection is typically a self-limited disease in immunocompetent individuals, the natural history and viral kinetics of HAV in solid…
2022 American Transplant Congress
Humoral and Cellular Immunity 6 Months After SARS-CoV-2 Infection in Solid-Organ Transplant Recipients
S. Morris¹, S. Courel², S. Pallikkuth³, S. Pahwa³, A. Fernandez⁴, S. Anjan¹, G. Guerra⁵, M. Alcaide¹, Y. Natori¹
¹Division of Infectious Disease, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, ²University of Miami Miller School of Medicine, Miami, FL, ³Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, ⁴Infectious Disease Associates of Tampa Bay, Tampa Bay, FL, ⁵University of Miami Jackson Memorial Hospital, Miami, FL
*Purpose: The purpose of this study was to evaluate long term humoral and cellular immunity generated following SARS-CoV-2 infection in solid organ transplant recipients (SOTR).*Methods:…
2022 American Transplant Congress
Randomized, Phase 4 Study Evaluating the Pharmacokinetics and Tolerability of the New Tacrolimus Tablet Formulation (Tacrobell Tab) in Kidney Transplant Recipients
A. Han¹, E. Cho¹, H. Y. Woo¹, C. Ara¹, H. Lee², Y. Kim³, Y. Park⁴, J. Oh⁴, S. Min¹, J. Ha¹
¹Department of Surgery, Seoul National University College of Medicine, Seoul, Korea, Republic of, ²Seoul National University Hospital, Seoul, Korea, Republic of, ³Department of Nephrology, Seoul National University College of Medicine, Seoul, Korea, Republic of, ⁴Department of Clnical Pharmacology, Seoul National University Hospital, Seoul, Korea, Republic of
*Purpose: Previous twice-a-day tacrolimus formulations available were capsular and of limited dose formulations (0.5mg, 1mg). Recently a new tablet formulation of tacrolimus with more diverse…
2022 American Transplant Congress
Prevalence of Mycophenolate Mofetil (MMF) Discontinuation and Outcomes in Pediatric Kidney Transplants (PKTX): A PNRC Study
A. Moudgil¹, K. Sgambat¹, E. Benoit², A. Jain³, M. Seifert⁴, C. Katsoufis⁵, L. Harshman⁶, A. Mansuri⁷, M. Somers⁸
¹Nephrology, Children's National Med. Ctr., Washington, DC, ²Nephrology, Boston's Children's Hospital, Boston, MA, ³Nephrology, Wayne State University, Troy, DC, ⁴Nephrology, The University of Alabama, Birmingham, AL, ⁵Nephrology, Holtz Children's Hospital, Miami, FL, ⁶Nephrology, University of Iowa, Iowa City, IA, ⁷Nephrology, Children's Hospital of Georgia, Augusta, GA, ⁸Nephrology, Boston Children's Hospital, Boston, MA
*Purpose: MMF is discontinued in PKTX for various reasons. In this Pediatric Nephrology Research Consortium (PNRC) study, we determined prevalence and reasons for MMF discontinuation…
2022 American Transplant Congress
Comparison of Immediate-Release Tacrolimus to Envarsus XR on the Development of Donor Specific Antibodies in Kidney Transplant Recipients
R. A. Arora, C. Kane, K. Lang, M. Kapugi, C. D'Agostino, K. Cunningham, S. H. Park
Northwestern Memorial Hospital, Chicago, IL
*Purpose: Major causes of de novo development of donor specific antibodies (DSA) after kidney transplant include medication noncompliance and immunosuppression minimization or elimination that may…
2022 American Transplant Congress
Humoral and Cellular Immune Response to a Third Dose Of SARS-CoV-2 Vaccine in Kidney Transplant Recipients on Belatacept
J. Mitchell¹, J. Alejo¹, T. P. Chiang¹, J. N. Blankson¹, A. H. Karaba¹, B. Woldemeskel¹, C. Garliss¹, A. Chang¹, A. Abedon¹, R. K. Avery¹, A. Tobian¹, A. B. Massie¹, J. Garonzik-Wang², D. L. Segev¹, W. Werbel¹
¹Johns Hopkins University, Baltimore, MD, ²University of Wisconsin, Madison, WI
*Purpose: Kidney transplant recipients taking belatacept (KTR-B) have poor immune response to two-dose SARS-CoV-2 vaccination. We sought to characterize the impact of an additional vaccine…
2022 American Transplant Congress
Incidence and Outcomes of CMV Infection in Pancreas Transplant with Thymoglobulin Induction: A Single Center Experience
W. Abusalah, A. Yadav
Thomas Jefferson University Hospital, Philadelphia, PA
*Purpose: CMV infection is a major infectious complication in pancreas transplant recipients (PTR). Incidence of CMV viremia in PTR with thymoglobulin induction and it's effect…
2022 American Transplant Congress
Efficacy and Safety of a Delayed Graft Function Protocol in Kidney Transplant Recipients
V. Vu¹, S. Bhayana², H. Sweiss¹, N. Castro¹, R. Hall¹, J. Nelson¹
¹University Health, San Antonio, TX, ²University of Texas Health Science Center at San Antonio, San Antonio, TX
*Purpose: To evaluate the efficacy and safety of a protocol increasing the net state of immunosuppression for adult kidney transplant recipients (KTR) with delayed graft…